tipifarnib has been researched along with fr 148083 in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (fr 148083) | Trials (fr 148083) | Recent Studies (post-2010) (fr 148083) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 23 | 0 | 21 |
| Protein | Taxonomy | tipifarnib (IC50) | fr 148083 (IC50) |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | 0.8 | |
| Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (human) | 0.017 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 2.5393 | |
| Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (human) | 0.009 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.0296 | |
| Transcription factor p65 | Homo sapiens (human) | 0.25 | |
| TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | Homo sapiens (human) | 0.0087 | |
| Phospholipase A-2-activating protein | Homo sapiens (human) | 0.011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for tipifarnib and fr 148083
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |